Abstract: In this letter, we present a novel recursive approach aimed at refining parameter estimation within the Errors-in-Variables (EIV) framework. Our method integrates the Weighted Total Least ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Abstract: The main concern for many applications (for example, for Coriolis Mass Flow Meter signal processing in two-phase flow conditions) is to track several domain poles of signals with minimum ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...